Skip to main content
Erschienen in: Tumor Biology 5/2015

01.05.2015 | Research Article

Involvement of NEDD9 in the invasion and migration of gastric cancer

verfasst von: Jin Feng, Jinpeng Zhao, Haibin Xie, Yong Yin, Guanghua Luo, Jun Zhang, Yuehua Feng, Zhong Li

Erschienen in: Tumor Biology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Recent studies have demonstrated that neural precursor cell expressed, developmentally downregulated 9 (NEDD9) is highly expressed in various tumor tissues and cell lines. However, research on the role of NEDD9 in gastric cancer (GC) is rare, and the potential mechanism in tumor progression has not yet been explored. In this study, we investigated the role and mechanism of NEDD9 in GC. The expression of NEDD9 in GC tissues and cell lines was measured by immunohistochemistry, qRT-PCR, and Western blot, respectively. Inhibiting NEDD9 expression was carried out by siRNA transfection, and upregulating of NEDD9 was via NEDD9 overexpression plasmid. The ability of proliferation, migration, and invasion was detected by MTT assay, scratch wound assay, and transwell assay, respectively. The expression of vimentin, E-cadherin, Zeb1, and Zeb2 was measured by Western blot and qRT-PCR. We found that NEDD9 expression was dramatically increased both in GC tissues and cell lines, and the expression was significantly related to GC development. Knockdown of NEDD9 in SGC-7901 strongly inhibited its malignant capacity in vitro. Meanwhile, upregulation of NEDD9 in GES-1 increased the malignant capacity. In addition, the expression of vimentin, Zeb1, and Zeb2 was positively correlated with NEDD9, while E-cadherin was opposite. Collectively, our findings suggest that NEDD9 acts as an oncogene and promotes GC metastasis via EMT.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet], 2013. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet], 2013.
2.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.CrossRefPubMed
4.
Zurück zum Zitat Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol. 1996;16:3327–37.CrossRefPubMedPubMedCentral Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol. 1996;16:3327–37.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y, Morimoto C. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta 1 integrinmediated signaling in lymphocytes. J Exp Med. 1996;184:1365–75.CrossRefPubMed Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y, Morimoto C. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta 1 integrinmediated signaling in lymphocytes. J Exp Med. 1996;184:1365–75.CrossRefPubMed
6.
Zurück zum Zitat Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene. 2006;25(12):1721–32.CrossRefPubMed Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene. 2006;25(12):1721–32.CrossRefPubMed
7.
Zurück zum Zitat Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125(7):1269–81.CrossRefPubMed Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125(7):1269–81.CrossRefPubMed
8.
Zurück zum Zitat Kong C, Wang C, Wang L, Ma M, Niu C, Sun X, et al. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One. 2011;6(7):e22666.CrossRefPubMedPubMedCentral Kong C, Wang C, Wang L, Ma M, Niu C, Sun X, et al. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One. 2011;6(7):e22666.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Li Y, Bavarva JH, Wang Z, Guo J, Qian C, Thibodeau SN, et al. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene. 2011;30(23):2633–43.CrossRefPubMedPubMedCentral Li Y, Bavarva JH, Wang Z, Guo J, Qian C, Thibodeau SN, et al. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene. 2011;30(23):2633–43.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 1992;185:1155–61.CrossRefPubMed Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 1992;185:1155–61.CrossRefPubMed
11.
Zurück zum Zitat O’Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res. 2007;67(19):8975–9.CrossRefPubMedPubMedCentral O’Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res. 2007;67(19):8975–9.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 2010;67(7):1025–48.CrossRefPubMed Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 2010;67(7):1025–48.CrossRefPubMed
13.
Zurück zum Zitat Singh M, Cowell L, Seo S, O’Neill G, Golemis E. Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys. 2007;48(1):54–72.CrossRefPubMedPubMedCentral Singh M, Cowell L, Seo S, O’Neill G, Golemis E. Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys. 2007;48(1):54–72.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Feng Y, Wang Y, Wang Z, Fang Z, Li F, Gao Y, et al. The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. Cancer Res. 2012;72:6502–11.CrossRefPubMedPubMedCentral Feng Y, Wang Y, Wang Z, Fang Z, Li F, Gao Y, et al. The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. Cancer Res. 2012;72:6502–11.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Zhang Q, Wang H, Ma Y, Zhang J, He X, Ma J, et al. Overexpression of Nedd9 is a prognostic marker of human gastric cancer. Med Oncol. 2014;31(7):33.CrossRefPubMed Zhang Q, Wang H, Ma Y, Zhang J, He X, Ma J, et al. Overexpression of Nedd9 is a prognostic marker of human gastric cancer. Med Oncol. 2014;31(7):33.CrossRefPubMed
16.
Zurück zum Zitat Liu Y, Wang D, Zhao KL, Zhu JW, Yin HB, Wei YZ, et al. NEDD9 overexpression correlates with poor prognosis in gastric cancer. Tumour Biol. 2014;35(7):6351–6.CrossRefPubMed Liu Y, Wang D, Zhao KL, Zhu JW, Yin HB, Wei YZ, et al. NEDD9 overexpression correlates with poor prognosis in gastric cancer. Tumour Biol. 2014;35(7):6351–6.CrossRefPubMed
17.
Zurück zum Zitat Shi R, Wang L, Wang T, Xu J, Wang F, Xu M. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma. Med Oncol. 2014;31(3):852.CrossRefPubMed Shi R, Wang L, Wang T, Xu J, Wang F, Xu M. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma. Med Oncol. 2014;31(3):852.CrossRefPubMed
18.
Zurück zum Zitat Zeng G, Gao L, Yu RK. Reduced cell migration, tumor growth and experimental metastasis of rat F-11 cells whose expression of GD3-synthase is suppressed. Int J Cancer. 2000;88(1):53–7.CrossRefPubMed Zeng G, Gao L, Yu RK. Reduced cell migration, tumor growth and experimental metastasis of rat F-11 cells whose expression of GD3-synthase is suppressed. Int J Cancer. 2000;88(1):53–7.CrossRefPubMed
19.
Zurück zum Zitat Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, et al. Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem. 2005;280(50):41439–48.CrossRefPubMed Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, et al. Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem. 2005;280(50):41439–48.CrossRefPubMed
20.
Zurück zum Zitat Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516–23.CrossRefPubMed Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516–23.CrossRefPubMed
21.
Zurück zum Zitat Kiyokawa E, Hashimoto Y, Kurata T, Sugimura H, Matsuda M. Evidence that DOCK180 up-regulates signals from the CrkII-p130(Cas) complex. J Biol Chem. 1998;273:24479–84.CrossRefPubMed Kiyokawa E, Hashimoto Y, Kurata T, Sugimura H, Matsuda M. Evidence that DOCK180 up-regulates signals from the CrkII-p130(Cas) complex. J Biol Chem. 1998;273:24479–84.CrossRefPubMed
22.
Zurück zum Zitat Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a “molecular switch” for induction of cell migration. J Cell Biol. 1998;140:961–72.CrossRefPubMedPubMedCentral Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a “molecular switch” for induction of cell migration. J Cell Biol. 1998;140:961–72.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Sadok A, Marshall C: Rho-GTPases: Masters of cell migration. Small GTPases 5. pii: e29710, 2014. Sadok A, Marshall C: Rho-GTPases: Masters of cell migration. Small GTPases 5. pii: e29710, 2014.
24.
Zurück zum Zitat Natarajan M, Stewart J, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD. HEF1 is a necessary and specific downstream effcctor of FAK that promotes the migration of glioblastoma cells. Oncogene. 2006;25:1721–32.CrossRefPubMed Natarajan M, Stewart J, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD. HEF1 is a necessary and specific downstream effcctor of FAK that promotes the migration of glioblastoma cells. Oncogene. 2006;25:1721–32.CrossRefPubMed
25.
Zurück zum Zitat Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011;6(7):e21650.CrossRefPubMedPubMedCentral Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011;6(7):e21650.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Jin Y, Li F, Zheng C, Wang Y, Fang Z, Guo C, et al. NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition. Int J Cancer. 2014;134(10):2294–304.CrossRefPubMed Jin Y, Li F, Zheng C, Wang Y, Fang Z, Guo C, et al. NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition. Int J Cancer. 2014;134(10):2294–304.CrossRefPubMed
27.
Zurück zum Zitat Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, et al. Epithelial-tomesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009;22(5):668–78.CrossRefPubMedPubMedCentral Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, et al. Epithelial-tomesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009;22(5):668–78.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.CrossRefPubMed Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.CrossRefPubMed
29.
Zurück zum Zitat Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.CrossRefPubMed Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.CrossRefPubMed
Metadaten
Titel
Involvement of NEDD9 in the invasion and migration of gastric cancer
verfasst von
Jin Feng
Jinpeng Zhao
Haibin Xie
Yong Yin
Guanghua Luo
Jun Zhang
Yuehua Feng
Zhong Li
Publikationsdatum
01.05.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2999-1

Weitere Artikel der Ausgabe 5/2015

Tumor Biology 5/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.